Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2000-07-10
2004-12-28
Bugaisky, Gabriele (Department: 1653)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S069200, C435S069700, C435S226000, C435S006120, C435S440000, C435S320100, C435S325000, C435S252300, C435S254110, C536S023200, C536S023500
Reexamination Certificate
active
06835555
ABSTRACT:
This invention relates to newly identified polynucleotides, polypeptides encoded by such polynucleotides, the use of such polynucleotides and polypeptides, as well as the production of such polynucleotides and polypeptides. More particularly, the polypeptides of the present invention are interleukin-1 &bgr; converting enzyme like apoptosis protease-3 and interleukin-1 &bgr; converting enzyme like apoptosis protease-4, sometimes hereinafter referred to collectively as “ICE-LAP-3 and 4”. The invention also relates to inhibiting the action of such polypeptides.
It has recently been discovered that an interleukin-1&bgr; converting enzyme (ICE) is responsible for cleaving pro-IL-1&bgr; into mature and active IL-1&bgr; and is also responsible for programmed cell death (or apoptosis), which is a process through which organisms get rid of unwanted cells. The present invention is directed to ICE-LAP-3 and 4 which are structurally related to ICE.
In the nematode
Caenorhabditis elegans
, a genetic pathway of programmed cell death has been identified (Ellis, R. E., et al. Annu. Rev. Cell Biol., 7:663-698 (1991)). Two genes, ced-3 and ced-4, are essential for cells to undergo programmed cell death in
C. elegans
(Ellis, H. M., and Horvitz, H. R., Cell, 44:817-829 (1986)). Recessive mutations that eliminate the function of these two genes prevent normal programmed cell death during the development of
C. elegans
. The known vertebrate counterpart to ced-3 protein is ICE. The overall amino acid identity between ced-3 and ICE is 28%, with a region of 115 amino acids (residues 246-360 of ced-3 (SEQ ID NO:13) and 164-278 of ICE (SEQ ID NO:14)) that shows the highest identity (43%). This region contains a conserved pentapeptide, QACRG (residues 356-360 of ced-3 (SEQ ID NO:13)), which contains a cysteine known to be essential for ICE function. The ICE-LAP-1 and 2 polypeptides of the present invention also have the same conserved pentapeptide and the cysteine residue which is essential for ICE function.
The similarity between ced-3 and ICE suggests not only that ced-3 might function as a cysteine protease but also that ICE might act as a vertebrate programmed cell death gene. ced-3 and the vertebrate counterpart, ICE, control programmed cell death during embryonic development, (Gagliarnini, V. et al., Science, 263:826:828 (1994).
ICE mRNA has been detected in a variety of tissues, including peripheral blood monocytes, peripheral blood lymphocytes, peripheral blood neutrophils, resting and activated peripheral blood T lymphocytes, placenta, the B lymphoblastoid line CB23, and monocytic leukemia cell line THP-1 cells (Cerretti, D. P., et al., Science, 256:97-100 (1992)), suggesting that ICE may have an additional substrate in addition to pro-IL-1&bgr;. The substrate that ICE acts upon to cause cell death is presently unknown. One possibility is that it may be a vertebrate homolog of the
C. elegans
cell death gene ced-4. Alternatively, ICE might directly cause cell death by proteolytically cleaving proteins that are essential for cell viability.
The mammalian gene bcl-2, has been found to protect immune cells called lymphocytes from cell suicide. Also, crmA, a cow pox virus gene protein product inhibits ICE's protein splitting activity.
In accordance with one aspect of the present invention, there is provided novel mature polypeptides, as well as biologically active and diagnostically or therapeutically useful fragments, analogs and derivatives thereof. The polypeptide of the present invention is of human origin.
In accordance with another aspect of the present invention, there are provided isolated nucleic acid molecules encoding a polypeptide of the present invention including mRNAs, DNAs, cDNAs, genomic DNAs as well as analogs and biologically active and diagnostically or therapeutically useful fragments thereof.
In accordance with yet a further aspect of the present invention, there are provided processes for producing such polypeptides by recombinant techniques comprising culturing recombinant prokaryotic and/or eukaryotic host cells, containing a nucleic acid sequence encoding a polypeptide of the present invention, under conditions promoting expression of said protein and subsequent recovery of said protein.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotide encoding such polypeptides for therapeutic purposes, for example, as an antiviral agent, an anti-tumor agent and to control embryonic development and tissue homeostasis.
In accordance with yet a further aspect of the present invention, there is also provided nucleic acid probes comprising nucleic acid molecules of sufficient length to specifically hybridize to a nucleic acid sequence of the present invention.
In accordance with yet a further aspect of the present invention, there are provided antibodies against such polypeptides.
In accordance with yet another aspect of the present invention, there are provided antagonists to such polypeptides, which may be used to inhibit the action of such polypeptides, for example, in the treatment of Alzheimer's disease, Parkinson's disease, rheumatoid arthritis, septic shock and head injury.
In accordance with still another aspect of the present invention, there are provided diagnostic assays for detecting diseases or susceptibility to diseases related to mutations in the nucleic acid sequences encoding a polypeptide of the present invention.
In accordance with yet a further aspect of the present invention, there is provided a process for utilizing such polypeptides, or polynucleotides encoding such polypeptides, for in vitro purposes related to scientific research, for example, synthesis of DNA and manufacture of DNA vectors.
These and other aspects of the present invention should be apparent to those skilled in the art from the teachings herein.
REFERENCES:
patent: 5552536 (1996-09-01), Nicholson et al.
patent: 2075662 (1993-02-01), None
patent: 0 533 226 (1993-03-01), None
patent: WO96/33268 (1996-10-01), None
GeneSeq Accession No. T66992 (Aug. 5, 1997) Idun Pharm., Inc. et al., “Apototic protease Mch3-alpha cDNA”.
GeneSeq Accession No. T66970 (Jul. 21, 1997) Vertex Pharm., Inc., “Cysteine protease CMH-1 cDNA”.
GeneSeq Accession No. T66993 (Aug. 5, 1997) Idun Pharm., Inc., “Crysteine protease Mch3-beta cDNA”.
GeneSeq Accession No. W15247 (Jul. 21, 1997) Vertex Pharm., Inc, “Cysteine protease CMH-1”.
GeneSeq Accession No. W15262 (Aug. 5, 1997) Idun Pharm., Inc., “Apototic protease Mch3-alpha”.
GeneSeq Accession No. W15263 (Aug. 5, 1997) Idun Pharm., Inc., “Cysteine protease Mch3-beta”.
GenBank Accession No. U39613 (Jan. 19, 1996) Duan et al., “Human cysteine protease ICE-LAP3 mRNA”.
GenBank Accession No. U37448 (Dec. 14, 1995) Pernandes-Alnemri et al., “Human Mch3 isoform alpha (Mch3) mRNA”.
GenBank Accession No. U40281 (Jan. 27, 1996) Lippke et al., “Human cysteine protease CMH-1 mRNA”.
GenBank Accession No. U67319 (Mar. 19, 1997) Juan et al., “Human Lice2 beta cysteine protease mRNA”.
GenBank Accession No. U67320 (Mar. 19, 1997) Juan et al., “Human Lice2 gamma cysteine protease mRNA”.
GenBank Accession No. U37449 (Dec. 14, 1995) Fernandes-Alnemri et al., “Human Mch3 isoform beta (Mch3) mRNA”.
GenBank Accession No. H91868 (Nov. 29, 1995) Hillier et al., “ys81a06.rl Soares retina N2b4HRHomo sapienscDNA clone IMAGE:221170 5′ similar to SP:A49429 A49429 CED-3+Interleukin-1 Beta-Converting Enzyme Homolog—Caenorhabditis ;, mRNA sequence”.
GeneSeq Accession No. V05471 (Jul. 2, 1998) Univ. Michigan, “Nucleic acid encoding a protein designated YAMA”.
GeneSeq Accession No. T33567 (Dec. 6, 1996) Univ. Michigan, “Pro-Yama cDNA”.
GeneSeq Accession No. V32608 (Oct. 26, 1998) Merck Frosst Canada, Inc., “Mutant human apopain (caspase-3) pro-enzyme cDNA”.
GeneSeq Accession No. V32615 (Oct. 26, 1998) Merck Frosst Canada, Inc., “Mutant human apopain (caspase-3) pro-enzyme cDNA”.
GeneSeq Accession No. W00677 (Dec. 6, 1996) Univ. Michigan, “Pro-Yama”.
GeneSeq Accession No. W00372 (Jun. 26, 199
Hastings Gregg A.
He Wei-Wu
Hudson Peter L.
Rosen Craig A.
Bugaisky Gabriele
Human Genome Sciences Inc.
Human Genome Sciences Inc.
LandOfFree
Interleukin-1 &bgr; converting enzyme like apoptosis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interleukin-1 &bgr; converting enzyme like apoptosis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interleukin-1 &bgr; converting enzyme like apoptosis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3335448